GlassScriptPhysician profile
Mehra Hosseini
NPI 1205947884
$4,156.30
in general payments reported to CMS, 2019-2025
27 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $186 · 2021: $635 · 2022: $415 · 2023: $766 · 2024: $523 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947 · Education: $78.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.20 |
| Education | $78.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,192.14 | 2020-2025 | |
| Janssen Biotech, INC. | $921.55 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $393.94 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.64 | 2019-2025 | Xifaxan |
| Pfizer INC. | $167.63 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $145.26 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $140.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Mauna Kea Technologies, INC. | $139.44 | 2019 | |
| Celgene Corporation | $82.83 | 2021-2024 | Zeposia |
| Medtronic, INC. | $81.42 | 2023 | Gi Genius |
| Braintree Laboratories, INC. | $68.99 | 2022-2025 | Sutab, Suflave |
| Lilly USA, LLC | $64.74 | 2024-2025 | Omvoh |
| Genzyme Corporation | $63.85 | 2023 | |
| Celltrion USA INC. | $63.65 | 2023-2024 | Vegzelma, Yuflyma, Zymfentra |
| Qol Medical, LLC | $63.01 | 2023-2024 | Sucraid, Sucraid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $57.79 | 2019-2024 | |
| Allergan, INC. | $52.74 | 2019 | |
| Ucb, INC. | $49.10 | 2019 | |
| Daiichi Sankyo INC. | $38.73 | 2020-2021 | |
| Shionogi INC | $27.75 | 2019 | |
| Ferring Pharmaceuticals INC. | $26.16 | 2023 | Rebyota |
| Amgen INC. | $25.83 | 2023 | Avsola, Amjevita |
| Dova Pharmaceuticals | $21.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.99 | 2023 | Dupixent |
| Boston Scientific Corporation | $16.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.50 | 2023 | Imfinzi |
| Lexicon Pharmaceuticals, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehra Hosseini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.